Abstract
The ability to identify genetic mutations causing an increased risk of cancer represents the first widespread example of personalised medicine, in which genetic information is used to inform patients of their cancer risks and direct an appropriate strategy to minimise those risks. Increasingly, an understanding of the genetic basis of many cancers also facilitates selection of the most effective therapeutic options. The technology underlying genetic testing has been revolutionised in the years since the completion of the Human Genome Project in 2001. This has advanced knowledge of the genetic factors underlying familial cancer risk, and has also improved genetic testing capacity allowing a larger number of patients to be tested for a constitutional cancer predisposition. To use these tests safely and effectively, they must be assessed for their ability to provide accurate and useful results, and be requested and interpreted by health professionals with an understanding of their strengths and limitations. Genetic testing is increasing in its scope and ambition with each year that passes, requiring a greater proportion of the healthcare workforce to acquire a working knowledge of genetics and genetic testing to manage their patients safely and sensitively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ACMG Board of Directors (2015) ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 17:68–69
Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Meth 7:248–249
Bentley DR, Balasubramanian S, Swerdlow HP et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53–59
Bergner AL, Bollinger J, Raraigh KS et al (2014) Informed consent for exome sequencing research in families with genetic disease: the emerging issue of incidental findings. Am J Med Genet Part A 164:2745–2752
Burke W, Matheny Antommaria AH, Bennett R, et al (2013) Recommendations for returning genomic incidental findings? We need to talk! Genet Med 15:854–859
Forbes SA, Beare D, Gunasekaran P et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805–D811
González-Pérez A, López-Bigas N (2011) Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 88:440–449
Green RC, Berg JS, Grody WW et al (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15:565–574
Haddow J, Palomaki G (2003) ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W (eds) Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Oxford University Press, Oxford
Hirschhorn JN, Gajdos ZKZ (2011) Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annu Rev Med 62:11–24
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protocols 4:1073–1081
Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921
Lee J-M, Ledermann JA, Kohn EC (2014) PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25:32–40
Margulies M, Egholm M, Altman WE et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–380
McKernan KJ, Peckham HE, Costa GL et al (2009) Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 19:1527–1541
Ng SB, Turner EH, Robertson PD et al (2009) Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461:272–276
Peters BA, Kermani BG, Sparks AB et al (2012) Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature 487:190–195
The Encode Project Consortium (2011) A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 9:e1001046
The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Thomas, E., Mohammed, S. (2016). Advances in Genetic Testing for Hereditary Cancer Syndromes. In: Pichert, G., Jacobs, C. (eds) Rare Hereditary Cancers. Recent Results in Cancer Research, vol 205. Springer, Cham. https://doi.org/10.1007/978-3-319-29998-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-29998-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29996-9
Online ISBN: 978-3-319-29998-3
eBook Packages: MedicineMedicine (R0)